Pandemic Darlings The pandemic economy, in original documents
Home Form 4: Inovio Pharmaceuticals, Inc. (INO), Kim Jong Joseph, transaction 02/01/2021Search ⌕

Form 4: Inovio Pharmaceuticals, Inc. (INO), Kim Jong Joseph, transaction 02/01/2021

Summary

Jong Joseph Kim, Chief Executive Officer and Director of INOVIO PHARMACEUTICALS, INC. [ INO ], reports selling 100,000 shares of Common Stock on 02/01/2021 at $ 15 under a Rule 10b5-1 trading plan. On 02/03/2021 a Common Stock Option for 62,500 shares was exercised at $ 4.56 and 62,500 shares were sold at a weighted average of $ 14.24, from trades between $13.81 and $14.64. Direct holdings after the sales are 1,078,313 shares, alongside 816,527 shares listed by a Family Limited Partnership and positions by spouse and by son and daughter accounts. The form is signed /s/ Jong Joseph Kim, 02/03/2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“Form 4: Inovio Pharmaceuticals, Inc. (INO), Kim Jong Joseph, transaction 02/01/2021.” Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-ino-4-filed2021-02-03-0001055726-21-000008-246faec427/, SHA-256 15b6f993f82f321c147d5cdd737a0cde0e62938ee8da1d9ac91225d3951a378a.

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Kim Jong Joseph (Last) (First) (Middle) 660 W. GERMANTOWN PIKE SUITE 110 (Street) PLYMOUTH MEETING PA 19462 (City) (State) (Zip) | Kim Jong Joseph | (Last) | (First) | (Middle) | 660 W. GERMANTOWN PIKE SUITE 110 | PLYMOUTH MEETING | PA | 19462 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol INOVIO PHARMACEUTICALS, INC. [ INO ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) Chief Executive Officer | X | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | Chief Executive Officer
3. Date of Earliest Transaction
 (Month/Day/Year) 02/01/2021
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 02/01/2021 | S (1) | 100,000 | D | $ 15 | 1,078,313 | D
Common Stock | 02/03/2021 | M | 62,500 | A | $ 4.56 | 1,140,813 | D
Common Stock | 02/03/2021 | S (1) | 62,500 | D | $ 14.24 (2) | 1,078,313 | D
Common Stock | 816,527 | I | By Family Limited Partnership
Common Stock | 33,533 | I | By Son: JK2
Common Stock | 33,563 | I | By Daughter: EK
Common Stock | 33,775 | I | By Son: JK1
Common Stock | 5,975 | I | By Spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Common Stock Option | $ 4.56 (3) | 02/03/2021 | M | 62,500 (3) | 03/11/2011 | 03/11/2021 | Common Stock | 62,500 (3) | $ 0 | 0 | D
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
2. These transactions were executed in multiple trades at prices ranging from $13.81 to $14.64, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
3. Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014.
Remarks:
/s/ Jong Joseph Kim | 02/03/2021
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File
SEC_INO_4_filed2021-02-03_0001055726-21-000008.xml
Size
20,240 bytes
SHA-256
15b6f993f82f321c147d5cdd737a0cde0e62938ee8da1d9ac91225d3951a378a
Our copy
SEC_INO_4_filed2021-02-03_0001055726-21-000008.xml
Original
www.sec.gov
Back to top